Exploiting the CRISPR/Cas9 PAM constraint for single-nucleotide resolution interventions

Yi Li; Saurabh Mendiratta; Kristina Ehrhardt; Neha Kashyap; Michael A. White; Leonidas Bleris

doi:10.1371/journal.pone.0144970

Exploiting the CRISPR/Cas9 PAM constraint for single-nucleotide resolution interventions

Yi Li, Saurabh Mendiratta, Kristina Ehrhardt, Neha Kashyap, Michael A. White, Leonidas Bleris

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

CRISPR/Cas9 is an enabling RNA-guided technology for genome targeting and engineering. An acute DNA binding constraint of the Cas9 protein is the Protospacer Adjacent Motif (PAM). Here we demonstrate that the PAM requirement can be exploited to specifically target single-nucleotide heterozygous mutations while exerting no aberrant effects on the wildtype alleles. Specifically, we target the heterozygous G13A activating mutation of KRAS in colorectal cancer cells and we show reversal of drug resistance to a MEK small-molecule inhibitor. Our study introduces a new paradigm in genome editing and therapeutic targeting via the use of gRNA to guide Cas9 to a desired protospacer adjacent motif.

Original language	English (US)
Article number	e0144970
Journal	PloS one
Volume	11
Issue number	1
DOIs	https://doi.org/10.1371/journal.pone.0144970
State	Published - Jan 1 2016

ASJC Scopus subject areas

General

Access to Document

10.1371/journal.pone.0144970

Cite this

@article{17455fbc3f2449178f369de0e54f1043,

title = "Exploiting the CRISPR/Cas9 PAM constraint for single-nucleotide resolution interventions",

abstract = "CRISPR/Cas9 is an enabling RNA-guided technology for genome targeting and engineering. An acute DNA binding constraint of the Cas9 protein is the Protospacer Adjacent Motif (PAM). Here we demonstrate that the PAM requirement can be exploited to specifically target single-nucleotide heterozygous mutations while exerting no aberrant effects on the wildtype alleles. Specifically, we target the heterozygous G13A activating mutation of KRAS in colorectal cancer cells and we show reversal of drug resistance to a MEK small-molecule inhibitor. Our study introduces a new paradigm in genome editing and therapeutic targeting via the use of gRNA to guide Cas9 to a desired protospacer adjacent motif.",

author = "Yi Li and Saurabh Mendiratta and Kristina Ehrhardt and Neha Kashyap and White, {Michael A.} and Leonidas Bleris",

note = "Publisher Copyright: {\textcopyright} 2016 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",

year = "2016",

month = jan,

day = "1",

doi = "10.1371/journal.pone.0144970",

language = "English (US)",

volume = "11",

journal = "PloS one",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "1",

}

TY - JOUR

T1 - Exploiting the CRISPR/Cas9 PAM constraint for single-nucleotide resolution interventions

AU - Li, Yi

AU - Mendiratta, Saurabh

AU - Ehrhardt, Kristina

AU - Kashyap, Neha

AU - White, Michael A.

AU - Bleris, Leonidas

N1 - Publisher Copyright: © 2016 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - CRISPR/Cas9 is an enabling RNA-guided technology for genome targeting and engineering. An acute DNA binding constraint of the Cas9 protein is the Protospacer Adjacent Motif (PAM). Here we demonstrate that the PAM requirement can be exploited to specifically target single-nucleotide heterozygous mutations while exerting no aberrant effects on the wildtype alleles. Specifically, we target the heterozygous G13A activating mutation of KRAS in colorectal cancer cells and we show reversal of drug resistance to a MEK small-molecule inhibitor. Our study introduces a new paradigm in genome editing and therapeutic targeting via the use of gRNA to guide Cas9 to a desired protospacer adjacent motif.

AB - CRISPR/Cas9 is an enabling RNA-guided technology for genome targeting and engineering. An acute DNA binding constraint of the Cas9 protein is the Protospacer Adjacent Motif (PAM). Here we demonstrate that the PAM requirement can be exploited to specifically target single-nucleotide heterozygous mutations while exerting no aberrant effects on the wildtype alleles. Specifically, we target the heterozygous G13A activating mutation of KRAS in colorectal cancer cells and we show reversal of drug resistance to a MEK small-molecule inhibitor. Our study introduces a new paradigm in genome editing and therapeutic targeting via the use of gRNA to guide Cas9 to a desired protospacer adjacent motif.

UR - http://www.scopus.com/inward/record.url?scp=84958214080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958214080&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0144970

DO - 10.1371/journal.pone.0144970

M3 - Article

C2 - 26788852

AN - SCOPUS:84958214080

SN - 1932-6203

VL - 11

JO - PloS one

JF - PloS one

IS - 1

M1 - e0144970

ER -

Exploiting the CRISPR/Cas9 PAM constraint for single-nucleotide resolution interventions

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this